Other drugs, such as pirfenidone, which targets TGFβ1, and lademirsen, which targets miR21, and pulmonary fibrosis drugs, such as nintedanib, PRM-151, epigallocatechin gallate, ziritaxestat, trametinib (MEK inhibitor), and anti–IL-11 antibody, are under study (Ruiz-Ortega et al. 2022). This evidence concerns the gene MAP2K7 and pulmonary fibrosis.